Provided by Tiger Trade Technology Pte. Ltd.

Atossa Genetics

5.59
-2.8850-34.04%
Post-market: 5.750.1600+2.86%19:59 EST
Volume:678.00K
Turnover:4.25M
Market Cap:48.14M
PE:-1.59
High:7.56
Open:7.23
Low:5.40
Close:8.48
52wk High:19.35
52wk Low:5.40
Shares:8.61M
Float Shares:8.61M
Volume Ratio:0.29
T/O Rate:7.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5221
EPS(LYR):-3.0396
ROE:-48.89%
ROA:-29.87%
PB:0.97
PE(LYR):-1.84

Loading ...

NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
Yesterday

Atossa Genetics trading halted, news pending

TIPRANKS
·
Jan 31

Atossa Therapeutics - Board Approves Reverse Stock Split at 15:1 Ratio - SEC Filing

THOMSON REUTERS
·
Jan 26

Atossa Therapeutics Announces 15-for-1 Reverse Stock Split

Reuters
·
Jan 26

Atossa Therapeutics' Founder and CEO Steven Quay, M.d., Ph.d. Named One of the Top 50 Healthcare Technology Ceos of 2025

THOMSON REUTERS
·
Jan 21

Stocks to Watch: Atossa Therapeutics, Union Pacific

Dow Jones
·
Jan 17

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Jan 17

FDA grants Atossa Therapeutics orphan drug designation for (Z)-endoxifen

TIPRANKS
·
Jan 16

BRIEF-Atossa Therapeutics Receives FDA "Study May Proceed" Letter For (Z)-Endoxifen

Reuters
·
Jan 06

FDA Clears Atossa Therapeutics to Proceed with (Z)-Endoxifen Trial for Metastatic Breast Cancer

Reuters
·
Jan 06

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

THOMSON REUTERS
·
Jan 06

Atossa Therapeutics Reports Promising (Z)-Endoxifen Trial Results for Breast Cancer Treatment and Risk Reduction

Reuters
·
Dec 15, 2025

Atossa Therapeutics Inc. Announces Date for Upcoming Special Meeting of Stockholders

Reuters
·
Dec 13, 2025

Why Are Shares Of Atossa Therapeutics Up Today?

Benzinga_recent_news
·
Dec 12, 2025

FDA Grants Rare Pediatric Disease Designation to Atossa Therapeutics' (Z)-Endoxifen for Duchenne Muscular Dystrophy

Reuters
·
Dec 11, 2025

Atossa Therapeutics Granted U.S. Patent for Enteric Oral (Z)-Endoxifen Formulations and Treatment Methods

Reuters
·
Dec 09, 2025

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

THOMSON REUTERS
·
Dec 09, 2025

Atossa Therapeutics and Insilico Medicine Identify (Z)-Endoxifen as Potential Glioblastoma Treatment in AI-Driven Study

Reuters
·
Dec 02, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 17, 2025

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Nov 14, 2025